Crossmark

Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways

Crossref DOI link: https://doi.org/10.1007/s00210-025-04215-7

Published Online: 2025-04-29

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aljorani, Randa Hisham https://orcid.org/0009-0000-8817-2242
Al-Zubaidy, Adeeb Ahmed https://orcid.org/0000-0002-5207-383X
Abdali, Nibrass Taher https://orcid.org/0009-0004-5240-2949
License Information

Text and Data Mining valid from 2025-04-29

Version of Record valid from 2025-04-29
More Information

Article History

Received: 14 December 2024

Accepted: 22 April 2025

First Online: 29 April 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. It was approved by the “Research Ethics Committee at the College of Medicine, Al-Nahrain University” following approval from the Institutional Review Board (IRB) committee (Animal ethical approval number: 202207175, date: 6 th November 2022).

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below